

Medtronic

Engineering the extraordinary

Partners for life

Together in ablation



25

years of ablation

Emprint™ ablation
system



Let's celebrate a generation of ablation innovation

Leading partners in life-transforming technology

We're lifelong partners in non-resectable liver tumor therapies – dedicated to revolutionizing liver disease management for 25 years. And we'll continue to help alleviate pain, restore health, and extend life, today and tomorrow.

Our pioneering ablation portfolio is a lifeline of trusted products that have stood the test of time in over 60 countries worldwide.¹ Let's celebrate a generation of innovation and shape the future of ablation together.

Emprint™ ablation system

A unique part of our lifeline of technology

We're celebrating the introduction of disruptive products like the Emprint™ ablation system with Thermosphere™ technology. Delivering first to market advanced technology for non-resectable liver tumor therapies.

We're driven by patient outcomes. Taking bold steps to preserve their future^{2,3} with innovative products for liver disease. And we're here to partner with you and deliver ablation therapies to help today's generation – and the next.



1997

2007

2008

2010*

2014

2017

2020



2022

Cool-tip™ RF system

Cool-tip™ RF ablation system and switching controller

Evident™ MW ablation system

Cool-tip™ RF ablation system E Series

Emprint™ ablation system with Thermosphere™ technology

Emprint™ SX ablation platform with Thermosphere™ technology

Emprint™ HP ablation generator with Thermosphere™ technology

25 years of ablation

Dedicated partners in non-resectable liver tumor therapies



Risk Information: While every attempt has been made to reduce patient and user risks, all surgeries using this device carry some residual risk, even when used by trained physicians.

Residual risks include: foreign body in patient, foreign body reaction, additional needle stick or puncture delay of treatment, post ablation syndrome, pain, fever, malaise, nausea, vomiting, myalgia, inflammation, hemorrhage, hemoptysis, hematoma, infection, peritonitis, abscess, ascites, seroma, wound dehiscence, adhesions, ischemia, necrosis, urinary retention, emphysema, pleural effusion, pneumothorax, pulmonary or upper respiratory fistula, hemothorax, dyspnea, biliary stenosis, biliary obstruction, biloma, cholangitis, biliary cirrhosis, haemobilia, gastrointestinal fistula, liver dysfunction, hepatic insufficiency, hepatic infarction, jaundice, colonic perforation, renal fistula, embolism, death, atrial fibrillation, tachycardia, cardiomyopathy, arteriovenous fistula, and cancer seeding.

Please refer to the product user manual for detailed information.

In the event that a serious incident has occurred related to device use, immediately report the event to the manufacturer, the competent authorities, and any other regulators as required.

References

1. Based on internal sales reports dated "September FY23", Emprint antenna sold based on a 3 year historical report.
2. Ruers T, Van Coevorden F, Punt CJ, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. *J Natl Cancer Inst.* 2017;109(9):dix015. doi:10.1093/jnci/dix015.
3. Thomas M. Drake, Ewen M. Harrison. Malignant Liver Tumours. *Surgery.* 2017;35(12):707-714.

[Learn more at medtronic.com/gi](https://www.medtronic.com/gi)